NWBO - Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?
When it comes to winning biotech stocks this year, coronavirus vaccine developers automatically come to many investors' minds. However, one of the top-performing stocks in the sector is Northwest Biotherapeutics (OTC: NWBO) , which focuses on immunotherapies that treat cancer, and has returned a staggering 408% since January.
The main reason why investors are so excited about Northwest Biotherapeutics' prospects is that the company's 14-year-long phase 3 clinical trial to evaluate its one and only immunotherapy candidate, DCVax-L, as a treatment for glioblastoma, has concluded. Should you consider buying the stock in anticipation of the data release? Let's find out together.
Image source: Getty Images.
For further details see:
Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?